


Anticancer agent 104

Cat. No.:	HY-149231
Molecular Formula:	C ₃₄ H ₄₇ F ₃ N ₂ O ₂ S ₂
Molecular Weight:	636.87
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Anticancer agent 104 has anticancer activity, and induces cancer cell apoptosis ^[1] .
In Vitro	Anticancer agent 104 (Compound 4I) (48 h) is toxic to HepG2 cells (IC ₅₀ : 31.39 μM) ^[1] . Anticancer agent 104 (10-200 μg/mL, 48 h) exhibits volume reduction, chromatin margination, and eventually formed apoptotic vesicles ^[1] . Anticancer agent 104 (10-100 μg/mL, 48 h) induces HepG2 cell apoptosis ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis ^[1]
	Cell Line: Calu-1, SK-BR-3, HUH-7, 786-O, SK-OV-3 cells
	Concentration: 0-200 μM approximately
	Incubation Time: 48 h
	Result: Shows cytotoxic activities with IC ₅₀ s of 78.34, 44.18, 75.18, 91.67, 112.19 μM.
	Apoptosis Analysis ^[1]
	Cell Line: HepG2 cells
	Concentration: 10, 50 and 100 μg/mL
	Incubation Time: 48 h
	Result: Showed apoptotic rate of 23.67%, 41.21% and 61.16% respectively.

REFERENCES

[1]. Zhang MW, et al. Design, synthesis and biological evaluation of matrine-dithiocarbamate hybrids as potential anticancer agents. Eur J Med Chem. 2023 Jun 5;254:115375.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA